Haisco Pharmaceutical Group Co. Ltd. has described bromodomain-containing protein 9 (BRD9) inhibitors or BRD9 degradation inducers reported to be useful for the treatment of cancer.
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have divulged fused benzoisoxazolyl compounds acting as histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for the treatment of neuroinflammation, neurodegeneration, pain, cancer, diarrhea, inflammatory bowel disease, irritable bowel syndrome and psychiatric disorders.
Merck Sharp & Dohme Corp. has disclosed pyrazolopyrimidine derivatives acting as DNA polymerase inhibitors reported to be useful for the treatment of herpes virus infection.
Biopolar Hongye (Nantong) Pharmaceutical Co. Ltd. and Hangzhou Hertz Pharmaceutical Co. Ltd. have described apoptosis regulator Bcl-2 wild-type, Bcl-2 (D103Y mutant) and/or Bcl-2 (G101V mutant) inhibitors reported to be useful for the treatment of cancer, infections, immunological and inflammatory disorders.
Oncobix Co. Ltd. has divulged novel heterocyclic-substituted pyrimidine derivatives acting as ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.
Shanghai Visonpharma Co. Ltd. has identified pyridine[4,3-d]pyrimidine compounds acting as Toll-Like receptor 7 (TLR7) and TLR8 agonists reported to be useful for the treatment of cancer and viral infection.
The U.S. Department of Health and Human Services has synthesized cannabinoid CB1 receptor antagonists reported to be useful for the treatment of cancer, metabolic, psychiatric, neurological, pain, gastrointestinal, inflammation, and substance abuse and dependence.
RSS